furazolidone has been researched along with Cardiac Failure in 8 studies
Furazolidone: A nitrofuran derivative with antiprotozoal and antibacterial activity. Furazolidone acts by gradual inhibition of monoamine oxidase. (From Martindale, The Extra Pharmacopoeia, 30th ed, p514)
furazolidone : A member of the class of oxazolidines that is 1,3-oxazolidin-2-one in which the hydrogen attached to the nitrogen is replaced by an N-{[(5-nitro-2-furyl)methylene]amino} group. It has antibacterial and antiprotozoal properties, and is used in the treatment of giardiasis and cholera.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Carvedilol is a non-selective beta-blocker with alpha-receptor blockade and antioxidant properties." | 5.32 | Chronic treatment with carvedilol improves ventricular function and reduces myocyte apoptosis in an animal model of heart failure. ( Doye, AA; Gwathmey, JK; Hajjar, RJ; Jabbour, G; Laste, N; Lebeche, D; Lee, MX; Okafor, CC; Perreault-Micale, C; Skiroman, K, 2003) |
| "Carteolol treatment increased beta-adrenergic receptor density, and the high carteolol dose restored SR Ca2+-ATPase and myofibrillar ATPase activities, along with creatine kinase, lactate dehydrogenase, aspartate transaminase, and ATP synthase activities, to normal." | 5.30 | Cellular and molecular remodeling in a heart failure model treated with the beta-blocker carteolol. ( Bristow, MR; DiSalvo, TG; Gwathmey, JK; Hajjar, RJ; Khan, F; Kim, CS; Matsumori, A, 1999) |
| "We have previously demonstrated that in furazolidone-induced congestive heart failure in turkeys the specific Ca(2+)-ATPase activity of myocardial sarcoplasmic reticulum (SR) is 60% increased in compensation for a 50% depression in net Ca(2+)-sequestration activity." | 3.68 | Myocardial calcium cycling defect in furazolidone cardiomyopathy. ( Julian, RJ; Mirsalimi, SM; O'Brien, PJ; Shen, H; Weiler, JE, 1991) |
| "Carvedilol is a non-selective beta-blocker with alpha-receptor blockade and antioxidant properties." | 1.32 | Chronic treatment with carvedilol improves ventricular function and reduces myocyte apoptosis in an animal model of heart failure. ( Doye, AA; Gwathmey, JK; Hajjar, RJ; Jabbour, G; Laste, N; Lebeche, D; Lee, MX; Okafor, CC; Perreault-Micale, C; Skiroman, K, 2003) |
| "Carteolol treatment increased beta-adrenergic receptor density, and the high carteolol dose restored SR Ca2+-ATPase and myofibrillar ATPase activities, along with creatine kinase, lactate dehydrogenase, aspartate transaminase, and ATP synthase activities, to normal." | 1.30 | Cellular and molecular remodeling in a heart failure model treated with the beta-blocker carteolol. ( Bristow, MR; DiSalvo, TG; Gwathmey, JK; Hajjar, RJ; Khan, F; Kim, CS; Matsumori, A, 1999) |
| "Newly hatched male White Pekin ducklings were fed furazolidone (FZ) at dosage of 750 mg/kg of feed for 4 weeks." | 1.27 | Furazolidone-induced congestive cardiomyopathy in ducklings: myocardial ultrastructural alterations. ( Ferrans, VJ; Van Vleet, JF, 1983) |
| "Free carnitine was elevated by 126% in left ventricle and by 54% in skeletal muscle of the furazolidone-treated turkeys (p less than 0." | 1.27 | Carnitine alterations in spontaneous and drug-induced turkey congestive cardiomyopathy. ( Borgwardt, B; Einzig, S; Judd, D; Noren, GR; Pierpont, ME; Staley, NA, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (50.00) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Okafor, CC | 1 |
| Perreault-Micale, C | 1 |
| Hajjar, RJ | 2 |
| Lebeche, D | 1 |
| Skiroman, K | 1 |
| Jabbour, G | 1 |
| Doye, AA | 1 |
| Lee, MX | 1 |
| Laste, N | 1 |
| Gwathmey, JK | 2 |
| Van Vleet, JF | 3 |
| Ferrans, VJ | 3 |
| O'Brien, PJ | 2 |
| O'Grady, M | 1 |
| Lumsden, JH | 1 |
| Holmberg, DL | 1 |
| Shen, H | 2 |
| Weiler, JE | 2 |
| Horn, RD | 1 |
| Mirsalimi, SM | 2 |
| Julian, RJ | 2 |
| Kim, CS | 1 |
| Khan, F | 1 |
| DiSalvo, TG | 1 |
| Matsumori, A | 1 |
| Bristow, MR | 1 |
| Pierpont, ME | 1 |
| Judd, D | 1 |
| Borgwardt, B | 1 |
| Noren, GR | 1 |
| Staley, NA | 1 |
| Einzig, S | 1 |
8 other studies available for furazolidone and Cardiac Failure
| Article | Year |
|---|---|
Chronic treatment with carvedilol improves ventricular function and reduces myocyte apoptosis in an animal model of heart failure.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Antioxidants; Apoptosis; Carbazo | 2003 |
Furazolidone-induced congestive cardiomyopathy in ducklings: regression of cardiac lesions after cessation of furazolidone ingestion.
Topics: Animals; Cardiomyopathies; Disease Models, Animal; Ducks; Furazolidone; Heart Failure; Male; Myocard | 1983 |
Furazolidone-induced congestive cardiomyopathy in ducklings: myocardial ultrastructural alterations.
Topics: Animals; Cardiomyopathies; Ducks; Furazolidone; Heart Failure; Male; Myocardium; Myofibrils; Poultry | 1983 |
Furazolidone-induced congestive cardiomyopathy in ducklings: lack of protection from selenium, vitamin E, and taurine supplements.
Topics: Animals; Cardiomyopathies; Ducks; Furazolidone; Heart Failure; Male; Poultry Diseases; Selenium; Tau | 1983 |
Clinical pathologic profiles of dogs and turkeys with congestive heart failure, either noninduced or induced by rapid ventricular pacing, and turkeys with furazolidone toxicosis.
Topics: Animals; Cardiac Pacing, Artificial; Dog Diseases; Dogs; Female; Furazolidone; Heart Failure; Male; | 1993 |
Cellular and molecular remodeling in a heart failure model treated with the beta-blocker carteolol.
Topics: Adenosine Triphosphate; Adenylyl Cyclases; Adrenergic beta-Antagonists; Animals; Blood Pressure; Bod | 1999 |
Myocardial calcium cycling defect in furazolidone cardiomyopathy.
Topics: Animals; Calcium; Calcium Channels; Calcium-Transporting ATPases; Cardiomyopathies; Disease Models, | 1991 |
Carnitine alterations in spontaneous and drug-induced turkey congestive cardiomyopathy.
Topics: Animals; Cardiomyopathy, Dilated; Carnitine; Furazolidone; Heart Failure; Hemodynamics; Liver; Myoca | 1985 |